jhavlek

Avatar

About Jennifer Havlek

This author has not yet filled in any details.
So far Jennifer Havlek has created 35 blog entries.
25 Nov, 2019

2019 SITC: Comprehensive profiling of tumor-immune interaction in anti-PD-1 treated melanoma patients reveals subject-specific tumor escape mechanisms

2019 SITC: Comprehensive profiling of tumor-immune interaction in anti-PD-1 treated melanoma patients reveals subject-specific tumor escape mechanisms Checkpoint inhibitor therapy has demonstrated meaningful antitumor activity for many patients, though the majority fail to achieve complete response. Thus, it is of particular interest to identify biomarkers and mechanisms that promote positive response to immunotherapy. In [...]

12 Sep, 2019

Karin Eastham

Karin Eastham has served on our board since September 2019. Ms. Eastham has over 35 years of experience in financial and operations management, primarily in life sciences companies. Ms. Eastham serves as a director for 3 additional public biotechnology companies, Nektar Therapeutics, Geron Corporation, and Veracyte, Inc. Her former public directorships include Illumina, Inc., MorphoSys [...]

30 Jul, 2019

Biomarker Challenge #2: Analysis of Complex Data

Biomarker Challenge #2: Analysis of Complex Data More accurate, predictive biomarker analysis may assist in the selection of effective combinatorial immunotherapy treatments for patients.  Additionally, the complexity of both the tumor and tumor microenvironment suggests a comprehensive approach is needed for robust characterization of the cancer ecosystem. The ImmunoID NeXTTM platform investigates key [...]

10 Jul, 2019

Biomarker Challenge #1: Limited Samples

Challenge #1: Comprehensive Biology from a Limited & Difficult Sample More accurate, predictive biomarker analysis may assist in the selection of effective combinatorial immunotherapy treatments for patients.  Additionally, the complexity of both the tumor and tumor microenvironment suggests a comprehensive approach is needed for robust characterization of the cancer ecosystem. The ImmunoID NeXTTM [...]

30 Apr, 2019

2019 AACR: Applying immunopeptidomics and machine learning to improve neoantigen prediction for therapeutic and diagnostic use

Applying immunopeptidomics and machine learning to improve neoantigen prediction for therapeutic and diagnostic use Neoantigens are increasingly critical in immuno-oncology as therapeutic targets for neoantigen-based personalized cancer vaccines (PCVs) and as potential biomarkers for immunotherapy response. However, optimizing technologies for identifying neoepitopes that are more likely to provoke an immune response remains an important [...]

30 Apr, 2019

2019 AACR: A comprehensive, highly accurate genomics platform for precision immunotherapy: Simultaneously characterize tumors and the TME from a single FFPE sample

A comprehensive, highly accurate genomics platform for precision immunotherapy: Simultaneously characterize tumors and the TME from a single FFPE sample While the success of checkpoint blockade has been hugely promising, it’s increasingly apparent that predicting response to immunotherapies and developing new ones requires a more comprehensive approach to tumor immunogenomic profiling. We believe this [...]

30 Apr, 2019

2019 AACR: T-cell receptor repertoire profiling using an augmented transcriptome

2019 AACR: T-cell receptor repertoire profiling using an augmented transcriptome Immunotherapy is growing as one of the most promising therapeutic approaches in clinical oncology practice. This brings with it an increasing need for comprehensive immuno-genomic profiling of tumors to better understand the interaction with the immune system. This includes profiling of the T and [...]

30 Apr, 2019

2019 AACR: Development and validation of an accurate exome-scale cfDNA detection platform

2019 AACR: Development and validation of an accurate exome-scale cfDNA detection platform Neoantigens are increasingly used as biomarkers for response to checkpoint blockade therapy and as therapeutic targets for neoantigen-based personalized cancer vaccines. Accurate identification of neoantigens requires comprehensive exome and transcriptome sequencing of both a tumor biopsy and a matched normal sample to [...]

1 Apr, 2019

Aaron Tachibana

Aaron Tachibana joined Personalis as Chief Financial Officer in March 2019, with more than fifteen years of executive financial management experience at large, medium, and small cap public and private companies. Prior to Personalis, Mr. Tachibana was Chief Financial Officer at Lumentum from August 2015 to September 2018.  Lumentum is a publicly listed optical and [...]